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Ischemic cardiovascular disorders, the leading 
cause of death and disability worldwide (Mathers 
and Loncar, 2006), are generated by occlusive 
arterial thrombi that are principally formed by 
activated platelets (Davì and Patrono, 2007). 
Enhanced platelet reactivity, which is associ-
ated with several pathological states such as 
dyslipidemia, diabetes, obesity, hypertension, 
or smoke, plays an important role in the patho-
physiology of occlusive arterial thrombi (Davì 
et al., 1997; Kabbani et al., 2001; Davì and   
Patrono, 2007). In fact, the activation of plate-
lets by the exposed subendothelial surface may 
proceed beyond the purpose of hemostasis and 
lead to occlusive thrombus formation when an 
excessive accumulation of substances facilitat-
ing thrombus growth and stability takes place 
(Davì et al., 1997; Kabbani et al., 2001; Weyrich 
et al., 2007; Brass et al., 2008). Several mole-
cules that facilitate the activation of platelets by 
primary stimuli, potentially transforming a nor-
mal hemostatic response in the formation of an 
occlusive thrombus, have been described recently 
(Podrez et al., 2007; Gresele et al., 2008a).
For most of these substances, a priming ac-
tivity on platelets has been characterized only 
in vitro (Brass et al., 2008; Gresele et al., 2008b) 
and little evidence is available so far for a role of 
this class of molecules in regulating platelet func-
tion in vivo (Gresele et al., 2008a). Moreover, a 
pathogenic role of platelet hyperresponsiveness 
in thrombus formation in vivo has so far only 
been hypothesized and not demonstrated.
Matrix metalloproteinase 2 (MMP-2), the 
most abundant MMP which is constitutively 
expressed in cells of mesenchymal origin (Galis 
and Khatri, 2002), is contained in platelets and 
released upon aggregation and displays a poten-
tiating effect on platelet activation in vitro 
(Sawicki et al., 1997; Kazes et al., 2000; Falcinelli 
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Platelet activation at a site of vascular injury is essential for the arrest of bleeding; how-
ever, excessive platelet activation at a site of arterial damage can result in the unwarranted 
formation of arterial thrombi, precipitating acute myocardial infarction, or ischemic stroke. 
Activation of platelets beyond the purpose of hemostasis may occur when substances 
facilitating thrombus growth and stability accumulate. Human platelets contain matrix 
metalloproteinase 2 (MMP-2) and release it upon activation. Active MMP-2 amplifies the 
platelet aggregation response to several agonists by potentiating phosphatidylinositol  
3-kinase activation. Using several in vivo thrombosis models, we show that the inactivation 
of the MMP-2 gene prevented thrombosis induced by weak, but not strong, stimuli in mice 
but produced only a moderate prolongation of the bleeding time. Moreover, using cross-
transfusion experiments and wild-type/MMP-2/ chimeric mice, we show that it is  
platelet-derived MMP-2 that facilitates thrombus formation. Finally, we show that  
platelets activated by a mild vascular damage induce thrombus formation at a downstream 
arterial injury site by releasing MMP-2. Thus, platelet-derived MMP-2 plays a crucial role 
in thrombus formation by amplifying the response of platelets to weak activating stimuli. 
These findings open new possibilities for the prevention of thrombosis by the development 
of MMP-2 inhibitors.
© 2009 Momi et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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The expression of mRNA for MMP-9, TIMP-1, and TIMP-2 
was also evaluated in mouse spleens, and it was found that 
although mRNA for MMP-9 was not significantly different 
between MMP-2/, MMP-2+/, and WT mice, mRNA for 
TIMP-1  and  TIMP-2  was  reduced  both  in  heterozygous 
(30% reduction for both) and in homozygous MMP-2/ 
mice (36 and 33% reduction, respectively).
MMP-2/ mice have hyporeactive platelets
MMP-2/  mice  had  a  normal  platelet  count  (949.000  ± 
68.000 vs. 1,047.000 ± 22.630 platelets/µl of WT mice; n = 10; 
P = NS) and platelets appeared ultrastructurally normal at 
electron microscopy (Fig. S1). Surface expression of the major 
platelet glycoproteins (GPIIb/IIIa, GPIb, GPVI, and CD9) 
did not differ between MMP-2/ and WT mice. Platelet 
ATP content was similar in WT and MMP-2/ mice (17.5 ± 
1.7 and 18.8 ± 0.75 nmol/108 platelets, respectively; n = 5). 
On the contrary, although platelet lysates of WT mice con-
tained MMP-2 (43.9 ± 2.1 ng/108 platelets; n = 5), platelets 
from MMP-2/ were completely devoid of it (<0.1 ng/108 
platelets; n = 5). 0.1 U/ml thrombin induced a rapid release of 
active MMP-2 in the supernatant of WT platelets (36.4 ± 
2.47 ng/108 platelets; n = 3) but not of platelets of MMP-2/ 
mice. A time course of the appearance of active MMP-2 on 
the surface of platelets upon activation was performed with 
gel-filtered WT mouse platelets by flow cytometry, using an 
antibody that specifically recognizes active MMP-2. Resting 
platelets did not express active MMP-2 on their surface. The 
expression of active MMP-2 on mouse platelets was evident 
already at 30 s (baseline = 2.5 ± 0.3%, 30 s = 9.3 ± 0.2% of 
positive platelets) after thrombin stimulation, reached a maxi-
mum at 2 min (21.4 ± 1.04% of positive platelets), and re-
mained expressed for up to 15 min (n = 3).
The ability of 0.5 ng/ml of human active MMP-2 to po-
tentiate mouse platelet aggregation and the time course of this 
effect was evaluated with washed platelets from WT mice. 
With all the agonists used (0.8 µg/ml collagen, 3 µM U46619, 
and 0.05 U/ml of purified human -thrombin), the potentia-
tion of platelet aggregation was maximal within 2 min and 
decreased thereafter to disappear in 30 min (Table S1). Plate-
lets of MMP-2/ mice revealed a significant functional de-
fect. In fact, although platelets from WT mice, as well as from 
MMP-2+/ mice, aggregated dose dependently in response to 
ADP (0.2, 0.4, 2, and 10 µM), collagen (2, 5, and 10 µg/ml), 
arachidonic acid (0.1, 0.4, and 0.6 mM), epinephrine (10 and 
100  µM),  U46619  (3  and  4  µM),  and  purified  human   
-thrombin (0.05 and 0.1 U/ml), platelets from MMP-2/ 
mice failed to aggregate in response to the lowest concentra-
tions of each of the agonists tested, and only the highest con-
centrations induced aggregation (Fig. 1 A; Table S2).
Secretion of dense granules in response to ADP or arachi-
donic acid (evaluated by the release of ATP) was also impaired 
in platelets from MMP-2/ mice (Fig. 1 B; Table S2). Similarly, 
the expression on the platelet surface of P-selectin, an -granule 
protein, in response to collagen, thrombin, or ADP was reduced 
in platelets from MMP-2/ mice (Fig. 1 C; Table S2).
et al., 2005). MMP-2 is randomly distributed in the cytosol of 
resting human platelets and is then translocated to the extra-
cellular space during aggregation (Sawicki et al., 1998). Active 
MMP-2, but not its proenzyme, amplifies the platelet aggre-
gation response to weak concentrations of a range of agonists 
acting on different receptors, such as U46619 (TxA2/PGH2 
receptor agonist), ADP, or thrombin (Sawicki et al., 1997; 
Kazes et al., 2000; Falcinelli et al., 2005) by functionally po-
tentiating phosphatidylinositol 3-kinase (PI3K) activation 
(Falcinelli et al., 2005). Enhanced activation of PI3K, in turn, 
magnifies the triggering of several other signaling events, like 
protein kinase C activation, calcium transients, and, ulti-
mately, integrin IIb3 activation, ending in the enhanced ex-
pression of fibrinogen-binding sites (Falcinelli et al., 2005; 
Choi et al., 2008; Santos-Martínez et al., 2008). The concen-
trations of MMP-2 that exert this priming activity are in the 
range of those secreted by activated platelets in vitro (Falcinelli 
et al., 2005). Moreover, the release of MMP-2 by activated 
platelets, in amounts similar to those found to potentiate plate-
let activation, occurs in vivo in healthy humans during pri-
mary hemostasis (Falcinelli et al., 2007) or in the coronary bed 
of patients with acute coronary syndromes during myocardial 
ischemia (Falcinelli, E., M. Leone, G. Cimmino, T. Corazzi, 
P. Golino, and P. Gresele. 2005. Congress of the International 
Society on Thrombosis and Haemostasis. Abstr. OR370).
Altogether, these observations suggest that MMP-2 may 
play a role in the regulation of platelet activation in vivo by 
amplifying the response to weak stimuli and, thus, leading to 
unrestrained thrombus formation (Gresele et al., 2008b). In 
this paper, using MMP-2/ and chimeric mice, we provide 
the first genetic evidence that platelet-released MMP-2 plays 
a role in promoting arterial thrombosis in vivo and that this 
represents one of the mechanisms producing a prothrombotic 
phenotype and transforming a normal hemostatic response to 
a vessel injury in the unwarranted formation of an occlusive 
thrombus. These findings identify the effect of MMP-2 on 
blood platelets as a novel potential therapeutic target for the 
prevention of thrombosis.
RESULTS
Phenotype and genotype data
Zymography of plasma, platelet lysates, and lung extracts 
confirmed that MMP-2 is not expressed in MMP-2 knock-
out mice. On the contrary, in WT mice MMP-2 was detect-
able by zymography in all three types of biological samples 
(unpublished data). Pro–MMP-2 was present in platelet ly-
sates (43.9 ± 2.1 ng/108 platelets) from WT mice, and throm-
bin, collagen, or ADP induced a rapid increase in the amount 
of active MMP-2 in the supernatant to a maximal value of 
36.4 ± 2.5 ng/108 platelets. As expected, active MMP-2 was 
not detected in the supernatant of platelets from MMP-2/ 
mice (unpublished data).
RT-PCR of spleen extracts confirmed that WT mice, 
but not MMP-2/ mice, contain MMP-2 messenger RNA 
(mRNA). MMP-2 mRNA was reduced by 51% in spleen 
extracts from MMP-2+/ mice, as compared with WT mice. JEM VOL. 206, October 26, 2009 
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Figure 1.  Impaired platelet function in MMP-2/ mice. (A) Aggregation of platelets from WT mice (blue, +/+) and from heterozygous (green, +/) or 
homozygous (red, /) MMP-2–deficient mice. PRP from four to six animals was pooled and stimulated with different agonists. Platelets from MMP-2/ 
mice did not aggregate in response to low concentrations of arachidonic acid, collagen, or ADP, which was different from platelets of WT mice, whereas 
higher concentrations of the stimuli induced irreversible aggregation. Platelets from MMP-2+/ mice aggregated almost normally in response to the agonists 
used. Arrows: addition of the agonist. Platelet aggregation tracings are representative of four independent experiments. (B and C) Secretion of dense granules 
in response to ADP, collagen (coll), or arachidonic acid (AA), assessed by the release of ATP (B), as well as secretion of -granules, evaluated by platelet  
P-selectin expression by flow cytometry (C), were defective with MMP-2/ platelets. (D) Fibrinogen binding to platelets activated by 10 µM ADP and assessed 
by flow cytometry was also impaired with platelets from MMP-2/ mice as compared with WT platelets. (E) The adhesion of MMP-2/ platelets to a  
collagen-coated surface, under flow conditions (3000 s1), was reduced as compared with WT platelets (n = 6). (F) Western blotting of phospho–Akt Ser473. 
Akt phosphorylation, induced by stimulation with thrombin, was almost absent with MMP-2/ platelets, whereas it was evident with WT platelets with the 
highest dose of thrombin. (G) Akt phosphorylation. Data from lane 1 in F were quantified by densitometry and expressed as arbitrary units. (H–J) Expression of   
P-selectin (H) or fibrinogen (I) on platelets, and circulating platelet-leukocyte aggregates (J), in blood collected 2 min after the i.v. injection of increasing volumes 
of a mixture of collagen plus epinephrine in WT and MMP-2/ mice. MMP-2/ mice show defective in vivo platelet activation and platelet-leukocyte ag-
gregate formation as compared with WT animals, especially when low doses of the platelet-activating challenge are used. Results in B–D, H, J, and K are ob-
tained from three independent experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01.2368 PLATELET MATRIX METALLOPROTEINASE 2 AND THROMBOSIS | Momi et al.
were totally or partially occluded by platelet thrombi in WT 
animals  than  in  MMP-2/  mice  when  low  doses  of  the 
thrombotic challenge were used (Fig. 2, B and C). The injec-
tion of collagen plus epinephrine dose-dependently induced 
a drop of the platelet count that was stronger in WT mice as 
compared with MMP-2/ mice, indicating that in vivo acti-
vation and sequestration was more sustained in WT than in 
knockout mice (Fig. 2 D).
Photochemically induced thrombosis of the femoral artery 
was correlated with the dose of rose Bengal infused. An oc-
cluding thrombus occurred after 13 ± 2.4 min (n = 5) and 7.6 ± 
0.5 min (n = 5) from the beginning of the irradiation with 20 
or 50 mg/kg of rose Bengal, respectively, in WT mice. In 
MMP-2/ mice, instead, the infusion of the lowest dose of 
rose Bengal (20 mg/kg) did not lead to the development of   
an occluding thrombus (>30 min; n = 7; P < 0.01 vs. WT), 
whereas blood flow stopped in 8.6 ± 1.6 min (n = 5; P = NS 
vs. WT) when the strongest thrombotic stimulus was used (50 
mg/kg of rose Bengal; Fig. 2 E). Thrombus size was 0.33 ± 
0.06 mg with 20 mg/kg of rose Bengal and 0.86 ± 0.17 mg 
with 50 mg/kg of rose Bengal (+165%; n = 5) in WT mice. 
When the weaker thrombogenic stimulus was used (20 mg/kg 
of rose Bengal), thrombus weight was particularly reduced in 
MMP-2/ mice, to 78% smaller on average than in WT mice, 
whereas it was only 28% smaller with the strongest stimulus 
(Fig. 2 F). Bleeding time was 175 ± 14 s (median 155 s; 95% 
confidence intervals [CIs] 143.3–205.7 s) in WT mice, 306.5 ± 
8.6 s (median 197.5 s; 95% CIs 124.2–488.8 s) in heterozygous 
mice (MMP-2+/; P < 0.01 vs. WT), and 555.5 ± 97.7 s 
(median 452.5 s; 95% CIs 334.5–776.5 s) in MMP-2/ (P < 
0.0001 vs. WT and P < 0.001 vs. heterozygous; Fig. 2 G).
Human pro–MMP-2 restores platelet function  
of MMP-2/ mice
To confirm that pro–MMP-2 is rapidly transformed into ac-
tive MMP-2 at the surface of activated mouse platelets, as was 
previously shown for human platelets (Kazes et al., 2000), 
gel-filtered platelets from MMP-2/ mice were preincu-
bated with 100 ng/ml of human pro–MMP-2 and stimulated 
Serum thromboxane B2 levels did not differ between WT 
and MMP-2/ mice (WT, 95 ± 13.6 ng/ml; MMP-2/, 92 ± 
10.1 ng/ml; n = 5; P = NS), excluding defective arachidonic 
acid metabolism as a cause of impaired secretion. Fibrinogen 
binding to platelets stimulated in vitro with 10 µM ADP was 
significantly  reduced  in  MMP-2/  as  compared  with  WT 
mice, whereas platelets from MMP-2+/ mice showed an inter-
mediate value (Fig. 1 D). Platelet adhesion to collagen, under 
flow conditions at high shear rate, was significantly lower in 
MMP-2/ mice as compared with WT mice (Fig. 1 E). The 
phosphorylation of Akt, the principal downstream effector of 
the  PI3K  signaling  pathway,  induced  by  stimulation  with 
thrombin was almost absent in platelets from MMP-2/ mice 
as compared with platelets from WT mice (Fig. 1, F and G).
The expression of P-selectin on circulating platelets was 
enhanced dose dependently by the i.v. injection of a mixture 
of collagen plus epinephrine, significantly more so in WT mice 
than in MMP-2/ mice (Fig. 1 H; Table I). Similarly, fibrino-
gen binding to platelets induced by the i.v. injection of colla-
gen plus epinephrine was also lower in MMP2/ as compared 
with WT mice (Fig. 1 I; Table I). Finally, platelet/leukocyte 
aggregates circulating in whole blood were enhanced by the   
i.v. injection of collagen plus epinephrine significantly more in 
WT mice than in MMP-2/ mice (Fig. 1 J; Table I).
MMP-2/ mice have a defective thrombotic response  
and mildly impaired hemostasis
The i.v. injection of collagen plus epinephrine in WT mice 
induced platelet pulmonary thromboembolism, with a dose-
dependent increase of mortality of the number of lung vessels 
occluded by platelet thromboemboli and a marked drop of 
the number of circulating platelets. MMP-2/ mice were 
partially protected against platelet pulmonary thromboembo-
lism. This was more evident when low doses of the throm-
bogenic challenge were used, whereas the thromboembolic 
response was close to normal when a strong stimulus was 
used (Fig. 2 A). Histological analysis of slices of lungs ob-
tained 2 min after the i.v. injection of collagen plus epineph-
rine showed that a significantly higher number of lung vessels 
Table I.  Platelet activation in vivo in collagen plus epinephrine-challenged WT and MMP-2/ mice
Parameter Collagen plus epinephrine WT mice MMP-2/ mice Reduction in MMP-2/ 
versus WT mice
P-value
µl % % %
P-selectin 80 27.7 ± 2.5 (n = 5) 28.6 ± 3.5 (n = 5) 0 NS
60 21.3 ± 3.7 (n = 5) 13.1 ± 1.6 (n = 5) 38.5 NS
40 10.5 ± 1.6 (n = 8) 4.4 ± 0.7 (n = 8) 58 0.01315
Platelet/leukocyte aggregates 60 43.84 ± 0.79 (n = 6) 36.2 ± 6.05 (n = 4) 17 NS
40 11.2 ± 0.9 (n = 10) 8 ± 0.9 (n = 10) 27.3 0.015
Fibrinogen binding 80 39.6 ± 3.67 (n = 5) 34.7 ± 4.01 (n = 5) 12.4 NS
60 32 ± 0.91 (n = 5) 24 ± 1.06 (n = 5) 25 0.00128
40 12.8 ± 1.62 (n = 5) 8.5 ± 0.44 (n = 5) 33.6 0.018
P-selectin (expressed as percentage of positive platelets): basal value, 4.9 ± 0.8% of positive cells; Platelet/leukocyte aggregates (expressed as percentage of leukocytes bound to 
platelets): basal value, 6.3 ± 0.6% of leukocytes bound to platelets; Fibrinogen binding (expressed as percentage of positive platelets): basal value, 3.3 ± 0.14% of positive cells.JEM VOL. 206, October 26, 2009 
ARTICLE
2369
Figure 2.  MMP-2/ mice have a defective thrombotic response. (A) Pulmonary thromboembolism-associated mortality induced by the i.v. injec-
tion of increasing volumes of collagen plus epinephrine in WT and MMP-2/ mice (n = 20 per group; *, P < 0.05 vs. WT). Mortality was lower in  
MMP-2/ mice with the lower, but not with the higher, doses of the thrombotic challenge. Error bars represent SEM. (B) Number of lung vessels occluded 
by platelet emboli in WT and in MMP-2/ mice 2 min after the injection of collagen plus epinephrine (n = 5 mice per group). Numbers represents means ± 
SEM of the percentage of occluded vessels out of the total number of lung vessels counted in 10 microscopic fields for each lung section. *, P < 0.05 ver-
sus WT. (C) Light microscopy (hematoxylin and eosin staining) of lungs after injection of 40 µl collagen plus epinephrine reveals platelet-rich thrombi 
(arrows) occluding lung vessels in WT mice but not in MMP-2/ mice. Bars, 100 µm. (D) Platelet count in WT and MMP-2/ mice 2 min after the i.v. 
injection of different doses of collagen plus epinephrine (n = 5 mice per group; P < 0.05 vs. WT). (E and F) Photochemically induced femoral artery throm-
bosis, as assessed by time-to-occlusion measured by laser Doppler (E) or as weight of the thrombus (F), was correlated to the amount of rose Bengal in-
fused. MMP-2/ mice showed markedly impaired thrombosis with the weaker stimulus (20 mg/kg of rose Bengal) but not with the strongest stimulus 
(50 mg/kg). Data are means ± SEM (n = 5 mice per group). (G) Tail-bleeding time in WT (n = 10), MMP-2+/ (n = 10), and MMP-2/ mice (n = 10). Results 
in A are obtained from four experiments; results in B and D–G are obtained from three experiments; and results in C are representative of three experi-
ments. Horizontal bars indicate the mean value. *, P < 0.05; **, P < 0.01; ***, P < 0.001.2370 PLATELET MATRIX METALLOPROTEINASE 2 AND THROMBOSIS | Momi et al.
Figure 3.  Human pro–MMP-2 restores platelet function of MMP-2 mice. Expression of active MMP-2 by mouse platelets. (A) The addition of 100 
ng/ml of human pro–MMP-2 to gel-filtered MMP-2/ platelets, followed by stimulation with human -thrombin, led to the expression of active MMP-2 
at the platelet surface at only 30 s after stimulation, reached a maximum at 2 min, and remained expressed at up to 15 min. Representative examples of 
flow cytometry plots of platelets stained with a specific rabbit anti–mouse active MMP-2 antibody: active MMP-2 expression at baseline, 30 s, and 2 and 
15 min after stimulation. White, aspecific IgG antibody; blue, gel-filtered MMP-2/ platelet baseline; red, expression of active MMP-2 on the surface of 
-thrombin–activated gel-filtered MMP-2/ platelets (n = 3). (B) 100 ng/ml of human pro–MMP-2 was added to gel-filtered platelets of MMP-2/ 
mice. Active MMP-2 was released in the supernatant of 0.1 U/ml of -thrombin–activated gel-filtered platelets 2 min after stimulation (lane 1, mouse 
MMP-2 standard; lane 2, sample buffer; lane 3, platelet supernatant 15 min after simulation; lane 4, platelet supernatant 2 min after simulation; lane 5, 
supernatant of resting platelets plus pro–MMP-2; lane 6, supernatant of resting platelets from MMP-2/ mice). (C)The addition of 100 ng/ml of human 
pro–MMP-2 to PRP of MMP-2/ mice (red), 2 min before stimulation with 0.05 U/ml thrombin, restores platelet aggregation (black) to a level similar to JEM VOL. 206, October 26, 2009 
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deeply thrombocytopenic (platelet count <5% of basal) by 
the i.v. injection of a rabbit anti–mouse platelet antiserum 
had a very prolonged bleeding time (≥900 s). The reconstitu-
tion of an almost normal platelet count by the transfusion of 
platelets from WT mice shortened the bleeding time by 47.5% 
(473 ± 89 s; P < 0.01; n = 11), whereas the reconstitution   
of  the  platelet  count  by  the  transfusion  of  platelets  from 
MMP-2/ mice shortened the bleeding time by only 12% 
(785.5 ± 61 s; n = 6; Fig. 4 A).
To confirm that platelet-derived MMP-2 was the cause of 
the hemostatic effect of transfused WT platelets and to exclude 
that other factors, such as plasma components, were involved, 
we created chimeric mice with MMP-2/ blood cells and 
WT vessels. The tail bleeding time of WT mice engrafted with 
bone marrow from WT animals (controls) was 296 ± 71 s (n = 
10), whereas MMP-2/ bone marrow chimeras had a pro-
longed bleeding time, which was similar to that of MMP-2/ 
mice. The bleeding time of MMP-2/ mice engrafted with 
bone marrow from WT mice was normal (Fig. 4 B).
The bleeding time of MMP-2/ mice transplanted with 
bone marrow from the same genotype (880 ± 144.6 s) was 
somewhat longer than that of MMP-2/ mice (555.5 ±   
97.7 s). Considering that in cross-transplantation experiments 
the reconstitution of the platelet count reached 70% of the 
normal, we performed experiments to assess the effect of a 
mild reduction of the platelet count on the bleeding time in 
MMP-2/ mice. The reduction of the number of circulat-
ing platelets to 70% in MMP-2/ mice by the administra-
tion of a low dose of a rabbit anti–mouse platelet antiserum 
induced a prolongation of the bleeding time to a level simi-
lar to that seen in MMP-2//MMP-2/ cross-transplanted 
animals (755 ± 57 s; n = 5).
Femoral artery thrombosis was photochemically induced 
in chimeric mice upon infusion of a low dose of rose Bengal 
(20 mg/kg). Blood flow stopped after 10.6 ± 2.6 min (n = 5) 
from  the  beginning  of  irradiation  in  chimeric  mice  with 
MMP-2+/+ blood cells. In contrast, in chimeric mice with 
MMP-2/ blood cells, blood flow stopped after 27.8 ± 2.2 
min (n = 5; P < 0.001 vs. chimeric mice with normal bone mar-
row; Fig. 4 C). The reduced thrombotic phenotype observed 
in MMP-2/ bone marrow chimeras was associated with defec-
tive platelet function: ex vivo platelet adhesion to a collagen-
coated surface under high shear was lower in MMP-2/ bone 
marrow chimeras than in normal bone marrow mice (Fig. 4 D); 
with human -thrombin. Active MMP-2, which is not pres-
ent on resting platelets, was already detectable at their surface 
30 s after stimulation, reached a maximum at 2 min, and re-
mained expressed at up to 15 min, as revealed by flow cy-
tometry (Fig. 3 A). Gelatinolytic activity at 68 kD (active 
MMP-2) was visualized by zymography in the supernatant of 
gel-filtered platelets from MMP-2/ mice incubated with 
100 ng/ml of human pro–MMP-2 and stimulated with   
-thrombin 2 min after stimulation (Fig. 3 B).
The addition of 100 ng/ml of human pro–MMP-2 to 
mouse platelet-rich plasma (PRP), 2 min before challenge with 
thrombin, potentiated platelet aggregation in both WT and 
MMP-2/ mice (Fig. 3 C). Preincubation of mouse-washed 
platelets with human 100 ng/ml of pro–MMP-2, 2 min before 
0.1 U/ml thrombin, enhanced Akt phosphorylation in plate-
lets from both WT (+53%) and MMP-2/ (+61.6%) mice 
(Fig. 3, D and E). The plasmatic half-life of human recombi-
nant pro–MMP-2, assessed after the i.v. injection of 500 ng of 
the proenzyme in MMP-2/ mice, was 19 min. Accordingly, 
in the subsequent experiments assessing the in vivo effects of 
human pro–MMP-2, all tests were performed between 2 and 
15 min from its i.v. injection. The injection of 100 ng/mouse 
of human pro–MMP-2 into MMP-2/ mice, 2 min before 
blood sampling, normalized ex vivo platelet adhesion (from   
37 ± 1.5 to 48.7 ± 1.5% of surface covered; n = 5; P < 0.01; 
Fig. 3 F). The i.v. injection of 100 ng/mouse of human   
pro–MMP-2, 15 min earlier, shortened the bleeding time in 
MMP-2/ mice (from 599.2 ± 74.1 to 222 ± 47 s; n = 10; 
Fig. 3 G). The thrombotic defect of MMP-2/ mice upon 
photochemically induced femoral artery injury was partially 
reversed by the i.v. injection of 100 ng/mouse of purified pro–
MMP-2 (n = 5; Fig. 3 H). In WT mice that were infused with 
a low dose of Rose Bengal (20 mg/kg), the injection of 100 
ng/mouse of human pro–MMP-2 significantly shortened the 
time to occlusion (from 13 ± 2.4 to 6.9 ± 0.6 min; n = 5; P < 
0.01), whereas it did not exert any appreciable effect in WT 
mice infused with 50 mg/kg of rose Bengal (from 7.6 ± 0.5 to 
6.4 ± 0.8 min; n = 5; P = NS).
Role of platelet-derived MMP-2 in hemostasis and thrombosis
To establish the contribution of MMP-2 derived from plate-
lets  in  the  hemostatic  and  thrombotic  defect  observed  in 
MMP-2/ mice, cross-transfusion experiments were per-
formed (Pitchford et al., 2004). WT mice that were made 
that of WT platelets (blue). Arrow denotes addition of the agonist. As expected, MMP-2 potentiated platelet aggregation of WT mice (green). (D) Preincu-
bation of washed platelets from MMP-2/ mice with 100 ng/ml of active human MMP-2 enhanced Akt phosphorylation only when the highest dose of 
thrombin (0.1 U/ml, lanes 3 and 4) was used as a stimulus, and preincubation with pro–MMP-2 of washed platelets from WT mice also enhanced Akt 
phosphorylation when the lowest dose of thrombin (0.05 U/ml) was used. In the absence of thrombin, MMP-2 has no effect on Akt phosphorylation (lane 5). 
Results in A–D are representative of three independent experiments. (E) Data from lanes 1–4 in D were quantified by densitometry and expressed as 
arbitrary units (white bars, mouse platelets added with pro–MMP-2; black bars, mouse platelets without the addition of pro–MMP-2). Results in A–E are 
representative of three independent experiments. (F) The i.v. injection of 100 ng/mouse of human pro–MMP-2 into MMP-2/ mice, 2 min before sam-
pling, restores ex vivo–impaired adhesion to a collagen-coated surface almost to the level observed in WT mice (n = 5). (G) The i.v. injection of 100 ng/
mouse of human pro–MMP-2 into MMP-2/ mice shortens the prolonged tail tip bleeding time (n = 10). (H) The i.v. injection of 100 ng/mouse of human 
pro–MMP-2 into MMP-2/ mice significantly increases photochemically induced femoral artery thrombosis, as measured by thrombus weight (n = 5). 
Results in E–H are the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 4.  Role of platelet-derived MMP-2 in hemostasis and thrombosis. (A) Mice made thrombocytopenic by the i.v. injection of a rabbit anti–
mouse platelet antiserum (rec, recipient) were transfused with platelets from either WT or MMP-2/ donor (don) mice. The tail tip bleeding time was 
significantly shortened by the transfusion of WT platelets but not of MMP-2/ platelets. (B) Chimeric mice were generated by the transplantation of 
bone marrow from donor WT or MMP-2/ mice into lethally irradiated recipient mice. Chimeras with WT bone marrow had a short bleeding time, 
whereas chimeras with MMP-2/ bone marrow had a prolonged bleeding time. (C–F) Photochemically induced femoral artery thrombosis was signifi-
cantly impaired in chimeras with MMP-2/ bone marrow (C). Ex vivo platelet function in chimeras with bone marrow from MMP-2/ mice was signifi-
cantly reduced as compared with chimeras with bone marrow from WT mice, as assessed by platelet adhesion to a collagen-coated surface (D), expression 
of P-selectin (E), or platelet-leukocyte aggregates (F) after the i.v. injection of a 60-µl mixture of collagen plus epinephrine. Results in A–F represent the 
mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
platelet P-selectin expression after the i.v. injection of 60 µl of 
collagen plus epinephrine was significantly lower in MMP-2/ 
bone marrow chimeras (Fig. 4 E); and similar findings were ob-
served for platelet/leukocyte aggregates (Fig. 4 F).
An arterial damage facilitates downstream thrombus 
formation by inducing the release of platelet MMP-2
When only a mild damage to the femoral artery was induced 
by the infusion of a low dose of rose Bengal (10 mg/kg; 
Fig. 5 A), no occluding thrombus occurred in WT mice (time 
to occlusion, >30 min; n = 5; Fig. 5 B). However, when a 
second arterial damage of identical intensity was induced 
downstream of the first insult (Fig. 5 A) a complete occlusion 
occurred (time to occlusion, 19.4 ± 2.3 min; n = 5; Fig. 5 B). 
When the sequence of the two arterial damages was in-
verted, first downstream and then upstream of the first insult, 
no occlusive thrombus occurred. These data suggest that the 
first arterial damage induces the release of mediators, pos-
sibly platelet derived, flowing downstream and potentiating 
the thrombotic response to a second stimulus. Indeed, a JEM VOL. 206, October 26, 2009 
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Figure 5.  A mild arterial damage facilitates downstream thrombus formation. (A) Cartoon illustrating the model. A first thrombogenic stimulus 
was induced by irradiation with green light during infusion of 10 mg/kg of rose Bengal. After 30 min, a second arterial damage was produced with the 
same modalities 0.5 cm downstream. The formation of an occluding thrombus was assessed by the measurement of blood flow with a laser Doppler 
probe. (B) Time to occlusion of the femoral artery, as assessed by laser Doppler, after repeated photochemical damage generated upon the infusion of a 
low dose of rose Bengal (10 mg/kg). In WT mice, the first photochemical insult does not induce thrombus formation, whereas an occlusion is observed 
after the second insult (n = 5). In MMP-2/ mice no thrombus forms after either insult (n = 5). (C and D) Expression of P-selectin (C) or MMP-2 (D) on 
platelets in blood collected downstream to the femoral insult (femoral artery) or in the systemic circulation (tail vein) in WT mice (n = 5). Platelet activa-
tion is observed in the femoral artery after the first arterial injury and, even more, after the second arterial injury, whereas no changes are detected in the 
systemic circulation. Results in B–D represent the mean ± SEM of five independent experiments. (E) The cross-transfusion of MMP-2/ platelets in  
platelet-depleted WT mice (n = 4) abolished thrombus formation after the second arterial insult, whereas thrombus formation was completely restored by 
the cross-transfusion of WT platelets into platelet-depleted MMP-2/ mice (n = 7). (F) Platelet-depleted MMP-2/ mice cross-transfused with platelets 
from WT mice showed platelet activation, as shown by platelet P-selectin increase after the first femoral artery insult and, even more, after the second 
femoral artery insult (n = 7). (G) The expression of P-selectin on platelets in blood collected downstream of the femoral insult was strikingly reduced in 
MMP-2/ mice (n = 4) as compared with WT mice and with platelet-depleted MMP-2/ mice cross-transfused with platelets from WT mice. Results in 
E–G represent the mean ± SEM of four independent experiments. *, P < 0.05; **, P < 0.01.2374 PLATELET MATRIX METALLOPROTEINASE 2 AND THROMBOSIS | Momi et al.
significant but localized platelet activation occurred after the 
first insult. In fact, the expression of P-selectin on the platelet 
surface rose from 2.4 ± 0.15% (baseline) to 19.9 ± 2.7% in 
blood collected immediately downstream of arterial damage 
(Fig. 5 C and Fig. S2), whereas it did not change on platelets 
from systemic blood tail vein (Fig. 5 C). One of the platelet 
activation–potentiating mediators may be MMP-2. Interest-
ingly, the expression of MMP-2 on platelets from blood 
withdrawn from the femoral artery was clearly enhanced after 
the first arterial injury (Fig. 5 D). Moreover, when an identi-
cal experiment was performed in MMP-2/ mice, no oc-
clusive thrombus formed either after the first or after the 
second downstream arterial insult (time to occlusion, >30 min; 
n = 4; Fig. 5 B). However, the cross-transfusion of WT 
platelets into platelet-depleted MMP-2/ mice restored the 
ability to form an occluding thrombus after the second down-
stream arterial insult (time to occlusion, 17.7 ± 2.65 min; n = 7; 
P < 0.05 vs. MMP-2/; Fig. 5 E). On the contrary, the cross-
transfusion of MMP-2/ platelets into platelet-depleted WT 
mice  also  abolished  thrombus  formation  after  the  second 
downstream damage to the femoral artery (time to occlusion, 
>30 min; n = 4). The expression of P-selectin and of 
MMP-2 (MMP-2 expression rose from 2.5 ± 0.5 to 18.2 ± 
4.6% of positive cells; n = 7) on platelets from blood collected 
immediately downstream of the arterial insult was signifi-
cantly enhanced in MMP-2/ mice cross-transfused with 
WT platelets after the photochemically induced arterial dam-
age (Fig. 5 F) as compared with MMP-2/ mice (Fig. 5 G).
To confirm the role of platelet-released MMP-2 in the 
thrombogenic response downstream to a first arterial damage, 
we infused systemically WT mice i.v. with 1 µg/mouse of 
the selective inhibitor of MMP-2, TIMP-2. Immediately, 
downstream of the first arterial insult, thrombus formation 
was abolished. Moreover, P-sel and MMP-2 expression at 
the surface of circulating platelets collected downstream of 
the second arterial insult were not different from baseline in 
TIMP-2–treated mice. In contrast, when the first weak, nor-
mally nonthrombogenic, arterial damage was performed in 
WT animals systemically infused with 100 ng/mouse of pro–
MMP-2, a thrombus had already developed after the first ar-
terial insult (time to occlusion, 15 ± 1.08 min).
All these data are consistent with a model in which localized 
platelet activation induced by a first arterial damage generates 
the release of platelet-stored pro–MMP-2, which gets rapidly 
activated to active MMP-2 and acts on the neighboring plate-
lets, making them hyperresponsive to a second stimulus like 
that generated by an arterial damage downstream to the first, to 
produce the formation of an occluding thrombus. The fact that 
this priming effect is essentially limited to the local circulatory 
bed derives from the transient nature of the priming effect of 
MMP-2 on platelets and from the dilution and/or inactivation 
in the systemic circulation of thrombogenic substances gener-
ated by localized platelet activation. This was confirmed by the 
subsequent experiments. The potentiating activity of human 
active MMP-2 on mouse platelet aggregation was maximal   
after  a  2-min  preincubation  and  it  almost  disappeared  after   
10 min. The infusion of thrombin-activated platelets directly 
into the femoral artery led to the appearance of P-selectin–
positive platelets in the systemic circulation within the first 
2 min after the injection (baseline, 3 ± 0.1%; 2 min, 7.7 ± 1.3% 
of positive platelets) and, thereafter, the expression of P-selectin 
on platelets in systemic blood disappeared.
DISCUSSION
We show in this paper that MMP-2/ mice are strongly pro-
tected against thrombosis induced by mild thrombogenic stim-
uli and have only a moderate impairment of hemostasis, that 
these alterations are the consequence of an abnormal platelet 
function, and that platelet-derived MMP-2 plays a crucial role 
in platelet activation and thrombus formation in vivo. Mice in 
which the MMP-2 gene has been disrupted do not suffer 
spontaneous bleeding and have an only moderately prolonged 
tail tip bleeding time as compared with WT mice, which is at 
variance from mice in which mechanisms of essential impor-
tance for the hemostatic function of platelets have been dis-
rupted, such as the GPIIb/IIIa-von Willebrand factor interaction 
(Hodivala-Dilke et al., 1999; Marx et al., 2008). In contrast, 
MMP-2/ mice are resistant to platelet-dependent thrombo-
sis, like pulmonary platelet thromboembolism (Gresele et al., 
1990; Momi et al., 2005) or photochemically induced throm-
bosis of the femoral artery (Kikuchi et al., 1998; Momi et al., 
2005). Several data suggest that the hemostatic defect and im-
paired thrombus formation of MMP/ mice are the result of 
defective platelet activation.
Indeed,  although  the  structure  and  number  of  platelets 
from MMP-2/ mice are normal, they show defective aggre-
gation in response to a variety of stimuli in vitro, reduced ad-
hesion to collagen, an impaired expression of platelet P-selectin, 
and diminished formation of platelet/leukocyte aggregates 
upon activation in vivo. Interestingly, defective platelet activa-
tion in vitro and in vivo is especially evident when weak stim-
uli are used, whereas it is much less apparent with strong 
stimuli, which is in agreement with an autocrine- or paracrine-
potentiating action of platelet-released MMP-2, as had been 
previously observed in vitro with human platelets (Sawicki   
et al., 1997; Falcinelli et al., 2005; Santos-Martínez et al., 2008). 
Defective platelet function of MMP-2/ mice was restored by 
the in vitro addition of human pro-MMP-2; moreover, the   
i.v. injection of human pro–MMP-2 into MMP-2/ mice re-
stored platelet function in terms of adhesion, aggregation, and 
P-selectin expression, indicating a pivotal role of MMP-2 for 
platelet activation. The human pro–MMP-2 injected into 
MMP-2/ mice was rapidly activated at the surface of plate-
lets, and the concentrations of active MMP-2 measured in 
plasma 2 min after the i.v. injection of pro–MMP-2 were in 
the range of those potentiating platelet activation in vitro   
(Falcinelli et al., 2005) and, thus, sufficient to reverse the deficit 
of platelet function of knockout mice.
The hemostatic defect and defective thrombus formation 
observed in mice in which the gene for MMP-2 has been dis-
rupted is mainly the result of the absence of MMP-2 from 
platelets, as shown by the observation that the cross-transfusion JEM VOL. 206, October 26, 2009 
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of  MMP-2/  platelets  into  thrombocytopenic  WT  mice 
does not correct the prolonged bleeding time. Similarly, chi-
meric mice in which the hematopoietic cell line derives from 
bone marrow cells of MMP-2/ mice have moderately im-
paired hemostasis and defective photochemical injury-induced 
arterial thrombosis, which is similar to what observed in 
MMP-2/ mice, whereas MMP-2/ mice with bone mar-
row derived from WT mice, and, therefore, with circulating 
platelets containing normal amounts of MMP-2 but with 
blood vessels devoid of MMP-2, showed a normal throm-
botic response upon arterial injury.
Altogether, our results are compatible with a model in 
which MMP-2 contained in platelets is released upon activa-
tion and acts in an autocrine and paracrine way on the neigh-
boring platelets, facilitating their activation response to 
physiological or pathological stimuli (Gresele et al., 2008b). 
This may become crucial in transforming a normal hemo-
static platelet activation response to mild vessel wall damage 
into an uncontrolled thrombotic response. This is confirmed 
by the observations that when two mild arterial insults are in-
duced sequentially, a thrombus forms only at the level of the 
second arterial damage downstream, that this phenomenon 
does not take place when circulating platelets are devoid of 
MMP-2, and that a selective MMP-2 inhibitor blocks down-
stream thrombus formation. These observations might ex-
plain why in the coronary bed of patients dying from acute 
myocardial infarction, where arterial plaques are widely dis-
seminated and more than one may be fissured or eroded, only 
a single acute occluding thrombus forms and is ultimately re-
sponsible for the acute ischemic event (Casscells et al., 2003). 
In contrast, pathological conditions in which circulating lev-
els of MMP-2 are enhanced as a result of the release of MMP-2 
from tissue, like ruptured inflammed atherosclerotic plaques 
(Galis et al., 1994; Galis and Khatri, 2002), may be associated 
with platelet hyperreactivity and with an enhanced tendency 
to thrombosis. Indeed, the release of MMP-2 in the coronary 
circulation of patients with acute coronary syndromes has 
been previously shown (Hojo et al., 2002; Falcinelli, E., M. 
Leone, G. Cimmino, T. Corazzi, P. Golino, and P. Gresele. 
2005. Congress of the International Society on Thrombosis 
and Haemostasis. Abstr. OR370). Our data, showing that an 
increase of circulating MMP-2, which is obtained by the in-
fusion of pro–MMP-2 in the systemic circulation of normal 
mice, transforms a mild nonthrombogenic stimulus into a 
strong thrombotic insult, are in favor of this hypothesis.
The important role played by platelet-released MMP-2 in 
arterial thrombosis identifies a new potential target for novel 
antithrombotic therapies. This is especially relevant if one con-
siders that aspirin intake does not prevent the in vivo release of 
MMP-2 from activated platelets (Falcinelli et al., 2007). The 
modulation of platelet-released MMP-2 by the development 
of specific monoclonal antibodies, of selective small molecule 
inhibitors, or by the application of gene silencing techniques 
can be one of the strategies to overcome the narrow gap be-
tween insufficient efficacy and excessive bleeding typical of cur-
rent antiplatelet drugs (Bhatt, 2007; Gresele et al., 2008b).
MATERIALS AND METHODS
Mice
C57BL/6  mice  were  purchased  from  Charles  River.  Mice  deficient  in 
MMP-2 were generated by gene targeting (Itoh et al., 1997; Wielockx et al., 
2001). The mutation heterozygous mice were obtained by crossing the chi-
meras to C57BL/6J one to five times, and then crossing to obtain the muta-
tion homozygous mice. These mice, and controls with matching genetic 
backgrounds, were bred as homozygous lines and were used at the age of 
8–12 wk. Mice were maintained with a 12:12-h light/dark cycle and had 
free access to food and water.
Genotyping of mice was performed by PCR analysis. Littermate tail tip 
DNA extraction was performed with the NucleoSpin tissue kit (M-Medical). 
Primer sequences used for mouse MMP-2 were 5-AACGATGGAGGCAC-
GAGTGGCC-3 (forward) and 5-TGTTTTAGGGGCGACATCGCCG-3 
(reverse). Primer sequences used for NEO detection were 5-CAACGCTAT-
GTCCTGATAGCGGTCC-3 and 5-CGTGTTCCGGCTGTCAGCG-
CAGG-3. In addition, the absence of MMP-2 protein in MMP-2/ mice 
was evaluated by zymography in plasma (Fig. S3). All animal protocols were 
approved by the Committee on Ethics of the University of Perugia (protocol 
186/2006 and 216/2007) and by the Italian Ministry of Public Health (autho-
rization protocol 74/2007 and 76/2007-B).
Assessment of MMPs expression by RT-PCR
MMP-2, MMP-9, TIMP-1, and TIMP-2 gene expression was assessed by 
RT-PCR in spleens taken from anesthetized WT, MMP-2/, and MMP-2+/ 
mice after perfusion with 20 ml of saline via left ventricular puncture at an 
infusion pressure ≤100 mm Hg, and immediately frozen in liquid nitrogen. 
Total RNA was extracted using an RNA purification kit (Absolutely RNA 
Miniprep kit; Agilent Technologies) and treated with DNase to avoid any 
genomic DNA contamination. Quantitative PCR was performed by moni-
toring in real time the increase in fluorescence of the Sybr Green Dye in a 
real-time PCR system (Mx 3000P; Agilent Technologies).
MMP-2, MMP-9, TIMP-1, and TIMP-2 segments of each resultant 
complementary DNA sample were PCR amplified in the presence of spe-
cific sense and antisense primers (200 nmol/liter each), using a power Sybr 
Green PCR Master Mix (Applied Biosystems) in a final reaction volume of 
25 µl. Cycling conditions were 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s (denaturation) and 60°C for 1 min (annealing and extension). 
2 microglobulin complementary DNA was amplified as an internal control. 
Each sample was tested in triplicate for each gene, and then a melting curve 
to ensure the specificity of amplification and the expression level of the gene 
was calculated by the CT method (Antonov et al., 2005).
Zymography
The gelatinolytic activity of MMP-2 was measured in plasma, in the superna-
tant of activated platelets, or in tissue extracts (20 µg of protein extracts) by 
zymography (Kleiner and Stetler-Stevenson, 1994), as previously described 
(Falcinelli et al., 2005). In brief, samples were mixed with SDS sample buffer 
without 2-mercaptoethanol and applied to 10% polyacrylamide gels copoly-
merized with 2 mg/ml of gelatin. After electrophoresis, gels were incubated 
for 1 h with 2.5% Triton X-100 to remove SDS and then overnight in buffer 
(50 mM Tris-HCl buffer with 20 mM NaCl, 5 mM CaCl2, and 0.01% Brij35, 
pH 7.5) at 37°C. Gels were then stained with 0.05% Coomassie Brilliant blue 
G-250 in a mixture of methanol, acetic acid, and water (3:1:6, vol/vol) and 
destained in 30% methanol with 10% acetic acid. Gelatinolytic activities were 
detected as transparent bands against the background of Coomassie Brillant 
blue–stained gelatin and quantified by analyzing the zymograms by densitom-
etry. Intensity of pro–MMP-2 and MMP-2 bands was quantified by densi-
tometry using the software Quantity One (version 4.1.1; Bio-Rad Laboratories). 
Gelatinolytic bands were compared with a standard curve built using increas-
ing amounts of recombinant human MMP-2 (EMD). Tissue or plasma protein 
content was measured by a protein assay (Bio-Rad Laboratories).
Platelet studies
Platelet count. Blood was collected by cardiac puncture from mice under 
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(clone 30-F11; BD). Subsequently, red blood cells were lysed by adding   
400 µl of water and, after 10 min, 1 ml of PBS.
Leukocytes were identified on the basis of their morphology and of the 
positivity for CD45. Platelet-leukocyte aggregates were quantified as the 
percentage of leukocytes positive for the platelet antigen CD41/CD61 or as 
the mean fluorescence intensity of the platelet antigen CD41/CD61 on the 
leukocyte surface. In some selected experiments, platelet P-selectin expres-
sion, fibrinogen binding, and platelet/leukocyte aggregates were assessed in 
blood collected from WT and MMP-2 / mice 2 min after the i.v. injection 
of a mixture of 150 µg/ml collagen plus 0.25 µM epinephrine.
For platelet MMP-2 expression, 5 µl of diluted whole blood was incu-
bated for 30 min with saturating concentrations of rabbit PE-labeled anti–
mouse CD41 (Leo.F2; Emfret Analytics) and goat anti–mouse MMP-2 (R&D 
Systems). Subsequently, an Alexa Fluor 488 anti–goat antibody (1:500; 
Invitrogen) was added. At the end of incubation period the reaction was 
stopped with 1 ml of 1% PFA.
For the study of the time course of expression of active MMP-2 on 
platelet surface, gel-filtered platelets from WT or MMP-2/ mice, incubated 
with 100 ng/ml of human pro–MMP-2, were activated by 0.1 U/ml of   
human -thrombin, and the reaction was stopped at 30 s and 2 and 15 min 
after the addition of -thrombin with 1 ml of 1% PFA. Active MMP-2 was 
assessed with a specific rabbit anti–mouse active MMP-2 antibody (Millipore) 
and a goat anti–rabbit antibody (1:500; Invitrogen) by flow cytometry.
Half-life of infused human pro–MMP-2 in mice. 500 ng of human 
recombinant pro–MMP-2 (Millipore) was injected i.v. in MMP-2/ mice 
(n = 15). After 2 min, and then every 30 min for a total of 120 min, whole 
blood was withdrawn in sodium citrate 4% (1:9 vol/vol) and quickly centri-
fuged to obtain platelet-poor plasma that was snap frozen for later determi-
nation of MMP-2 activity. The amount of active and total MMP-2 in mouse 
plasma  was  assed  by  ELISA  (MMP-2  Biotrak  activity  assay  system;  GE 
Healthcare) and by gelatin zymography. The plasma half-life of MMP-2 was 
determined as the time required by human MMP-2 to be degraded to half 
the concentration found in plasma 2 min after MMP-2 injection.
Platelet-derived thromboxane B2. For serum TxB2 measurement, non-
anticoagulated blood was collected in glass tubes and placed in a water bath at 
37°C for 60 min and then centrifuged (Patrono et al., 1980). Immunoreactive 
TxB2 was measured in unextracted highly diluted serum samples by a highly 
specific radioimmunoassay, as previously described (Gresele et al., 1987).
Akt phosphorylation. Akt phosphorylation was studied in washed platelets 
incubated for 2 min with activated human MMP-2 (Falcinelli et al., 2005) 
or with its vehicle before the addition of 0.05–0.1 U/ml thrombin. After 
10 min, the reaction was stopped with SDS-PAGE sample buffer, platelets 
were lysed with 2% SDS, and samples were carefully mixed and stored on 
ice. Proteins (measured by the Bradford assay) were analyzed by SDS-PAGE 
followed by immunoblotting, using an antibody against Akt or phospho-Akt 
Ser473 (1:2,000). In each electrophoresis well, an identical amount of proteins 
was loaded (20 µg; Falcinelli et al., 2005). Data were quantified using the 
QuantiScan software (BIOSOFT) and expressed as percentage of control   
(i.e., phosphorylation of Akt in thrombin-stimulated platelets). Human pro–
MMP-2 was activated by incubation with 1 mmol/liter APMA (para-amino-
phenylmercuric  acetate),  in  a  buffer  containing  50  mmol  L1  NaCl,   
5 mmol L-1 CaCl2, and 0.01% Brij 35, pH 7.5, at 37°C for 30 min (Falcinelli 
et al., 2005). APMA was then removed by filtration through Amicon filters 
(Microcon YM-10; Millipore).
Thrombosis models
Platelet  pulmonary  thromboembolism.  Collagen  plus  epinephrine– 
induced pulmonary thromboembolism was performed in MMP-2/ and in 
WT mice at 8–12 wk of age, using a method described previously (Gresele 
et al., 1990; Momi et al., 2005). Mice were caged and fed a regular diet for 
at least 1 wk before use. Thrombotic challenge was generated by the rapid 
i.v. injection of a mixture of 250 µg/ml collagen 1.5 µg/ml and epinephrine 
After thorough mixing, platelets were counted optically, using the Brecher-
Cronkite method (Brecher and Cronkite, 1950), by an operator unaware of 
the experimental groups (Momi et al., 2005).
Electron microscopy. Resting washed platelets were fixed for 4 h at 4°C, 
using cacodylate-HCl buffer (pH 7.4) containing 4% wt/vol of glutaralde-
hyde. The samples were then washed, maintained in cacodylate buffer for a 
further 4 h, and placed in 1% osmium tetraoxide and pelleted by centrifuga-
tion at 10,000 g for 30 s. Ultrathin sections of the platelet pellets were stained 
with uranyl acetate and lead citrate and observed with a transmission electron 
microscope at 80 kv (Optic EM208; Phillips; Gresele et al., 2009).
Platelet aggregation. The effect of MMP-2 on platelet aggregation was 
studied by the photometric method using either washed platelets (Vezza et al., 
2002) or PRP (Momi et al., 2005). Whole blood, drawn in 4% sodium 
citrate, was centrifuged at 150 g for 15 min to obtain PRP, which was then 
adjusted  to  300,000  platelets/µl  using  autologous  platelet-poor  plasma. 
Washed platelets were prepared in the presence of 0.2 µM PGI2, 50 U/ml 
heparin, and 0.01 mg/ml apyrase. Finally, platelets were resuspended in stan-
dard Tyrode’s buffer, pH 7.4, containing 0.35% BSA and 0.1% glucose, to 
give a final concentration of 250,000 platelets/µl. Gel-filtered mouse plate-
lets were prepared as previously described (Pulcinelli et al., 1998) and ad-
justed to 108/ml in Hepes-Tyrode’s buffer containing 0.1% BSA, pH 7.4. 
Platelet aggregation in response to different doses of collagen, arachidonic 
acid, ADP, purified human -thrombin (given by R. De Cristofaro, Catho-
lic University of Rome, Rome, Italy), or U46619, a stable analogue of TxA2 
(Vezza et al., 1993), was measured using an automatic platelet aggregation 
analyzer (APACT 4; Alfa Wassermann).
ATP secretion. Platelet ATP release was measured using firefly luciferase   
(7.3 µg/ml final concentration) and luciferin (800 U/ml final concentration). 
Luminescence generated by platelet-secreted ATP was monitored using a lumi-
aggregometer (Chrono-Log Corporation) and compared with that obtained 
by adding a known concentration of ATP standard (Emiliani et al., 2006).
Platelet  adhesion. Platelet adhesion to a collagen-coated surface under 
flow conditions was studied in a parallel-plate perfusion chamber (Sixma et 
al., 1998), as previously described (Momi et al., 2005). In brief, 0.5 ml of ci-
trated blood was passed through a perfusion chamber, over a plastic coverslip 
sprayed with 30 µg/cm2 collagen from equine tendon (Hormon-Chemie), 
at a wall shear rate of 3000 s1. The chamber was then perfused with BSA-
containing saline to remove all residual blood, and the coverslip was har-
vested, gently washed with 10 mmol/liter Hepes, and fixed with 0.25% 
glutaric dialdehyde in PBS. Adhering platelets were stained with May-
Grünwald/Giemsa, observed under an optical microscope, and the area cov-
ered by platelets was measured using a computerized image analyzer (Scion 
Image; National Institutes of Health; Momi et al., 2005).
Flow cytometry. Platelet surface P-selectin, MMP-2, and fibrinogen ex-
pression and circulating platelet-leukocyte aggregates were measured in whole 
blood by flow cytometry (EPICS XL-MCL; Beckman Coulter) as previously 
described (Ciferri et al., 2000; Pitchford et al., 2003). Blood samples, collected 
in 4% sodium citrate and diluted 1:10 with PBS, were stimulated with a mix-
ture of 0.5–5–20 µg/ml collagen plus 1–10–50 µM epinephrine, 30 µg/ml 
collagen, 0.05 or 0.1 U/ml of human -thrombin, or 20 µM ADP for 30 min 
under continuous stirring. Aliquots of 5 µl were then stained with a PE-
labeled anti-CD41 antibody (Leo.D2; Emfret Analytics) as a platelet identifier 
and with an FITC-labeled anti–P-selectin antibody (CD62P; Emfret Analyt-
ics) or with an FITC-labeled anti-fibrinogen antibody (P140-1; Emfret Ana-
lytics) for 30 min in the dark. The reaction was stopped with 1 ml of 1% PFA. 
P-selectin, MMP-2, and fibrinogen expression are reported as a percentage of 
positive cells. For platelet-leukocyte aggregates, 50 µl of undiluted whole 
blood were fixed with 1% PFA and incubated for 30 min with saturating 
concentrations of FITC-labeled anti-CD41/CD61 (IIb3; Leo.D2; Emfret 
Analytics) and Peridin chlorophyl protein–conjugated anti–mouse CD45 JEM VOL. 206, October 26, 2009 
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as previously described (Pitchford et al., 2004, 2008), or by  irradiation 
(10Gy; Clinac 600/C; Varian Medical Systems, Inc.). APAS was injected   
15 min before platelet transfusion. Platelet counts decreased by ≥95% within 
2 min, and a gradual increase in the number of circulating platelets was seen 
only 48 h after administration (Pitchford et al., 2004). In -irradiated mice, 
the number of circulating platelets dropped by 96% by day 5 and platelets 
were reinfused at that time. Approximately 1.0 × 109 platelets were reinfused 
into each animal, leading to a restoration of the platelet count to 80% of 
basal (Pitchford et al., 2004). Bleeding time measurements or photochemi-
cally induced arterial damage was performed 1 h after platelet transfusion.
Bone marrow transplantation. 8–12-wk-old, male and female MMP-2/ 
(C57BL/6 background) and C57BL/6 (WT) mice were used. Recipient 
mice were exposed to a single lethal dose of 8 Gy from an 18-mV photon 
beam linear accelerator (Clinac 600/C) with a focus-to-skin distance of 63 
cm and a dose rate of 0.2 Gy/min. After irradiation, all mice not receiving 
bone marrow transplantation died within 14 d. Donor bone marrow cells 
were collected into PBS by flushing the shafts of the femur and tibia. The 
cells were suspended and washed with PBS, and then red blood cells were 
lysed with ammonium chloride–potassium buffer and the remaining cells 
were washed twice with PBS. Finally, bone marrow cells were resuspended 
at a final concentration of 20 × 106 cells per ml in PBS and, the day after total 
body irradiation, 10 × 106 cells/mouse were injected into recipient mice i.v. 
via the lateral tail vein (Ruggeri et al., 2002).
In some experiments MMP-2/ mice were used as donors and WT as 
recipients, in others WT mice were used as donors and MMP-2/ as recipi-
ents. Control experiments were performed by transplanting bone marrow 
from WT donors into WT recipients and from MMP-2/ donors into 
MMP-2/ recipients. 1 mo after bone marrow transplantation, both chime-
ric and control mice had almost normal platelet counts (746.000 ± 39.975 
and 800.000 ± 30.551 platelets/µl, respectively). MMP-2 activity by zymog-
raphy and MMP-2 expression by RT-PCR were assessed in blood cells, 
aorta, kidney, and lung extracts obtained from recipients 8 wk after bone 
marrow transplantation to ensure that full engraftment had taken place.
Statistics
Data are expressed as arithmetic means ± SEM and were analyzed by one way 
analysis of variance, followed by the Newman-Keuls multiple comparison tests 
between all groups. Differences in mortality were assessed by the Fisher’s exact 
test. All analyses were performed by Prism 4.0 (GraphPad Software, Inc.). 
A p-value of <0.05 was considered to be statistically significant.
Online supplemental material
Fig. S1 shows electron microscopy of resting platelets from MMP-2/ and 
WT mice. Fig. S2 shows flow cytometry plots of the expression of P-selectin 
and active MMP-2 on the platelet surface in WT and MMP-2/ mice, in 
blood collected at baseline and immediately downstream of an arterial dam-
age. Fig. S3 shows an example of zymography that confirms the absence of 
MMP-2 in MMP-2/ mice. Table S1 reports data on the potentiation of 
platelet aggregation induced by active MMP-2. Table S2 summarizes platelet 
aggregation, ATP release, and P-selectin expression in response to various 
agonists in WT and MMP-2/ mice. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20090687/DC1.
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into one of the tail veins. MMP-2/ and WT mice were challenged with 
increasing volumes (from 20 to 100 µl) of the collagen plus epinephrine 
mixture and mortality was recorded. The effect of the i.v. challenge with 
collagen plus epinephrine was evaluated as described; the cumulative end 
point was death of the animal or paralysis of the hind limbs for more than   
15 min (Gresele et al., 1990; Momi et al., 2005). In each session, at least five 
animals per experimental group were tested. Controls were run at the begin-
ning and at the end of each experimental session. At the end of each experi-
mental session, surviving animals were sacrificed by an overdose of anesthesia. 
Mice were accustomed to handling and the injections were performed by 
skilled investigators with minimal disturbance to the animals. Data are pre-
sented as a percentage of animals dead per total number of animals tested.
Lung histology. The total number of lung vessels occluded by platelet 
thrombi was counted by light microscopy in paraffin-embedded sections 
stained with hematoxylin and eosin (Momi et al., 2005).
Femoral  artery  thrombosis. Photochemical-induced femoral artery 
thrombosis was induced in anesthetized mice by a method described previ-
ously (Kikuchi et al., 1998; Momi et al., 2005). In brief, mice were anaes-
thetized by 60 mg/kg of intraperitoneal sodium pentobarbital and placed on 
a heated operating table. A 25G-needle venous butterfly was inserted in one 
of the tail veins for the infusion of rose Bengal. The left femoral artery was 
carefully exposed, and a laser Doppler probe (Transonic System Inc.) was 
positioned onto the branch point of the deep femoral artery, distal to the in-
guinal ligament, for monitoring blood flow. The exposed artery was ir-
radiated with green light (wavelength, 540 nm) of a Xenon lamp (L4887; 
Hamamatsu Photonics) equipped with a heat-absorbing filter via a 3-mm di-
ameter optic fiber attached to a manipulator. Light irradiation was protracted 
for 20 min. The infusion of 10–50 mg/kg of rose-Bengal was started 5 min 
after the beginning of irradiation and lasted for 5 min. The end point was set 
as the cessation of blood flow for >30 s. If no occlusion occurred after   
30 min, the time was recorded as 30 min (Kikuchi et al., 1998; Momi et al., 
2005). 1 h after the end of the irradiation period, the femoral artery was ex-
cised and opened, and the thrombus was removed, dried at 37°C for 24 h, 
and then weighed. In some experiments, arterial damage was induced se-
quentially at two different sites of the femoral artery by two irradiation in-
juries  separated  from  one  another  by  30  min,  with  the  second  0.5  cm 
downstream of the first. For flow cytometry measurement of platelet   
P-selectin or platelet MMP-2 expression, blood was collected immediately   
after the first or the second vessel injury by arterial puncture at a femoral ar-
tery site distal to the injury or systemically from a tail vein.
To assess the detectability on the systemic circulation of localized plate-
let activation in the femoral artery, platelets obtained from WT mice were 
isolated by gel filtration and activated with 0.1 U/ml of purified human   
-thrombin for 15 min. Thrombin was neutralized with equimolar hirudin 
(Huo et al., 2003), and then 3 × 108 activated platelets were injected directly 
into the femoral artery of recipient mice. Blood for the detection of platelet 
P-selectin expression by flow cytometry was collected after platelet injection 
systemically, from a tail vein, at 2, 5, 10, and 15 min.
Bleeding time. Bleeding time was measured by the tail tip transection 
method, as previously reported (Momi et al., 2005). In brief, mice were po-
sitioned in a special immobilization cage that keeps the tail of the animal 
steady and immersed in saline thermostated at 37°C. After 2 min, the tip of 
the tail was transected with a razor blade at 2 mm from its end. The tail 
was immediately reimmersed in thermostated saline and time taken to stop 
bleeding was measured. The end point was the arrest of bleeding lasting for 
more than 30 s. Bleeding was recorded for a maximum of 900 s.
Cross-transfusion experiments. In some selected experiments, platelets 
were isolated by centrifugation at 150 g for 10 min from whole blood of do-
nor mice anticoagulated with acid citrate dextrose (1:6, vol/vol). The PRP 
obtained was pooled and infused in recipient mice that had been previously 
rendered deeply thrombocytopenic by one single i.v. injection of a saturat-
ing amount (100 µl) of an anti–mouse anti-platelet serum (APAS), prepared 2378 PLATELET MATRIX METALLOPROTEINASE 2 AND THROMBOSIS | Momi et al.
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